Miolo, GianMaria and Bidoli, Ettore and Lombardi, Davide and Santeufemia, Davide Adriano and Capobianco, Giampiero and Dessole, Francesco and Scalone, Simona and Spazzapan, Simon and Sorio, Roberto and Tabaro, Gianna and Veronesi, Andrea (2012) Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages? Archives of Gynecology and Obstetrics, Vol. 285 (2), p. 499-503. eISSN 1432-0711. Article.
Full text not available from this repository.
Objective: To evaluate the disease control rate (DCR) in heavily pretreated and relapsed ovarian cancer patients re-challenged with a weekly paclitaxel schedule and to establish whether a correlation between dose intensity, progression-free interval (PFI) and overall survival (OS) exists.
Methods: Retrospective data were collected from 30 heavily pretreated metastatic ovarian cancer patients who received 80 mg/m(2)/week paclitaxel regimen.
Results: The treatment was well tolerated and showed a DCR in 70% of the patients, with only one case of grade 3 hematological toxicity. One patient (3%) showed a complete response, 15 patients (50%) a partial response and five patients (17%) a stabilization of their disease. The regimen was mostly used as a fourth-line chemotherapy (range 2-7). The median dose intensity in responding patients was 57.5 mg/m(2)/week and in those with progressive disease 49.7 mg/m(2)/week. (p = 0.20). PFI and OS were increased in the responder patient groups with a log-rank test of 25.64 (p < 0.001) and 15.10 (p = 0.0001), respectively.
Conclusions: Weekly administration of paclitaxel was active and well tolerated as a salvage therapy for heavily pretreated ovarian cancer patients.
I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore
Repository Staff Only: item control page